Martin Babler Buys 15,650 Shares of Alumis Inc. (NASDAQ:ALMS) Stock

Alumis Inc. (NASDAQ:ALMS) CEO Martin Babler purchased 15,650 shares of the firm’s stock in a transaction dated Tuesday, April 1st. The shares were bought at an average price of $6.44 per share, with a total value of $100,786.00. Following the purchase, the chief executive officer now owns 106,454 shares in the company, valued at $685,563.76. The trade was a 17.23 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Alumis Stock Performance

Shares of NASDAQ ALMS opened at $10.05 on Friday. The business has a 50-day simple moving average of $5.52 and a two-hundred day simple moving average of $8.24. Alumis Inc. has a 52 week low of $3.18 and a 52 week high of $13.53.

Analyst Ratings Changes

ALMS has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Alumis in a report on Wednesday, March 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. Finally, Oppenheimer began coverage on shares of Alumis in a report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $26.00.

Hedge Funds Weigh In On Alumis

A number of large investors have recently modified their holdings of ALMS. BNP Paribas Financial Markets bought a new stake in Alumis during the 3rd quarter worth approximately $27,000. Wells Fargo & Company MN increased its holdings in shares of Alumis by 77.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock worth $69,000 after purchasing an additional 3,823 shares during the period. Northern Trust Corp raised its position in shares of Alumis by 4.3% in the fourth quarter. Northern Trust Corp now owns 111,326 shares of the company’s stock worth $875,000 after buying an additional 4,587 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Alumis by 4.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company’s stock valued at $891,000 after buying an additional 4,808 shares during the period. Finally, Barclays PLC grew its position in Alumis by 33.9% during the fourth quarter. Barclays PLC now owns 24,581 shares of the company’s stock worth $193,000 after buying an additional 6,221 shares in the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.